Based on the results obtained from the cross-analysis of three different statistical analyses performed on the cDNA array data, ESR1/ERα emerged as the premier gene, in accordance with its well established prognostic and predictive value for endocrine therapy in breast cancer [35-38], and reinforced the gene signature identified in this study. This evidence concerns the gene ESR1 and breast carcinoma.